Literature DB >> 10080151

Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats.

I Sakaida1, K Hironaka, K Uchida, K Okita.   

Abstract

The aim of this study was to investigate whether an iron chelator, deferoxamine (DFO) can prevent lipid peroxidation, resulting in reduced liver injury as well as reducing preneoplastic lesions induced by a choline-deficient L-amino acid-defined (CDAA) diet. CDAA diet administration resulted in an increased serum ALT level (367 +/- 58) after two weeks, but simultaneous DFO treatment for two weeks reduced this elevation of ALT as well as malondialdehyde (MDA) production in the liver. Feeding rats a CDAA diet for 12 weeks led to the development of severe liver fibrosis and preneoplastic lesions detected as enzyme-altered lesions. DFO treatment prevented the expression of activated stellate cells, resulting in the reduction of liver fibrosis as well as reducing the development of preneoplastic lesions. These results indicate that iron chelation can reduce the development of preneoplastic lesions in a CDAA diet model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080151     DOI: 10.1023/a:1026661508553

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  45 in total

1.  Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo.

Authors:  I Sakaida; K Uchida; Y Matsumura; K Okita
Journal:  J Hepatol       Date:  1998-03       Impact factor: 25.083

Review 2.  The significance of chemically-induced hepatocellular altered foci in rat liver and application to carcinogen detection.

Authors:  G M Williams
Journal:  Toxicol Pathol       Date:  1989       Impact factor: 1.902

3.  Rapid appearance of hypomethylated DNA in livers of rats fed cancer-promoting, methyl-deficient diets.

Authors:  E Wainfan; M Dizik; M Stender; J K Christman
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

4.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.

Authors:  C Niederau; R Fischer; A Sonnenberg; W Stremmel; H J Trampisch; G Strohmeyer
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

5.  Experimental liver cirrhosis induced by alcohol and iron.

Authors:  H Tsukamoto; W Horne; S Kamimura; O Niemelä; S Parkkila; S Ylä-Herttuala; G M Brittenham
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

6.  Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis?

Authors:  P Bedossa; K Houglum; C Trautwein; A Holstege; M Chojkier
Journal:  Hepatology       Date:  1994-05       Impact factor: 17.425

7.  Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells.

Authors:  M Parola; M Pinzani; A Casini; E Albano; G Poli; A Gentilini; P Gentilini; M U Dianzani
Journal:  Biochem Biophys Res Commun       Date:  1993-08-16       Impact factor: 3.575

8.  Response to interferon alpha therapy is influenced by the iron content of the liver.

Authors:  D H Van Thiel; L Friedlander; S Fagiuoli; H I Wright; W Irish; J S Gavaler
Journal:  J Hepatol       Date:  1994-03       Impact factor: 25.083

9.  High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats.

Authors:  D Nakae; H Yoshiji; Y Mizumoto; K Horiguchi; K Shiraiwa; K Tamura; A Denda; Y Konishi
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

10.  Dissociation of the accumulation of single-strand breaks in DNA from the killing of cultured hepatocytes by an oxidative stress.

Authors:  J B Coleman; D Gilfor; J L Farber
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

View more
  11 in total

1.  The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis.

Authors:  Haiyan Jin; Shuji Terai; Isao Sakaida
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

2.  Stimulation of proliferation in the colorectal mucosa by gastrin precursors is blocked by desferrioxamine.

Authors:  Audrey Ferrand; Shamilah Lachal; Gianni Bramante; Suzana Kovac; Arthur Shulkes; Graham S Baldwin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-15       Impact factor: 4.052

3.  Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor beta1 (TGF-beta1)-mediated p27Kip1 expression.

Authors:  Gyesoon Yoon; Hyun-Jung Kim; Young-Sil Yoon; Hyeseong Cho; In K Lim; Jae-Ho Lee
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

4.  Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments.

Authors:  Takahiro Yamasaki; Issei Saeki; Isao Sakaida
Journal:  Hepatol Int       Date:  2014-01-29       Impact factor: 6.047

Review 5.  Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.

Authors:  Taro Takami; Takahiro Yamasaki; Issei Saeki; Toshihiko Matsumoto; Yutaka Suehiro; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 6.  Iron homeostasis in the liver.

Authors:  Erik R Anderson; Yatrik M Shah
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

7.  Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.

Authors:  Issei Saeki; Naoki Yamamoto; Takahiro Yamasaki; Taro Takami; Masaki Maeda; Koichi Fujisawa; Takuya Iwamoto; Toshihiko Matsumoto; Isao Hidaka; Tsuyoshi Ishikawa; Koichi Uchida; Kenji Tani; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

8.  Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.

Authors:  Hirofumi Harima; Seiji Kaino; Taro Takami; Shuhei Shinoda; Toshihiko Matsumoto; Koichi Fujisawa; Naoki Yamamoto; Takahiro Yamasaki; Isao Sakaida
Journal:  BMC Cancer       Date:  2016-08-31       Impact factor: 4.430

9.  Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model.

Authors:  Norikazu Tanabe; Taro Takami; Koichi Fujisawa; Toshihiko Matsumoto; Naoki Yamamoto; Isao Sakaida
Journal:  J Clin Biochem Nutr       Date:  2017-05-16       Impact factor: 3.114

10.  Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib.

Authors:  Naoki Yamamoto; Takahiro Yamasaki; Taro Takami; Koichi Uchida; Koichi Fujisawa; Toshihiko Matsumoto; Issei Saeki; Shuji Terai; Isao Sakaida
Journal:  J Clin Biochem Nutr       Date:  2016-03-15       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.